# Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Source: https://onco.cc/trials/nct04925479/  
OnCo record `nct04925479` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Asciminib in chronic myeloid leukaemia, run by Novartis Pharmaceuticals, now recruiting.

## Summary

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia is a phase 1/2 interventional study registered as NCT04925479 by Novartis Pharmaceuticals, with 34 participants planned, started 2021-12-27 and due to reach its primary completion in 2027-09-21. Interventions recorded: Asciminib Pediatric formulation group and Asciminib Adult formulation group.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04925479
- Phase: 1/2
- Setting: A Multi-center, Open-label Study to Determine the Dose and Safety of Oral Asciminib in Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP), Previously Treated With One or More Tyrosine Kinase Inhibitors
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT04925479: https://clinicaltrials.gov/study/NCT04925479

## Connected records

- cancers: [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- drugs: [Asciminib](https://onco.cc/drugs/asciminib/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct04925479.json